Completed PHASE2 INTERVENTIONAL 1-arm NCT00493649

Adj TC + Herceptin Early Stage Breast Cancer

Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab in HER2-Positive Early Stage Breast Cancer Patients

Sponsor: Sanofi

Conditions Breast Cancer

Interventions Cytoxan Herceptin Taxotere

Updated 7 times since 2017 Last updated: Sep 15, 2016 Started: Jun 30, 2007 Primary completion: Apr 30, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00493649, this PHASE2 trial focuses on Breast Cancer and remains completed. Sponsored by Sanofi, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi
US Oncology Research

Data source: US Oncology Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States , Albany, United States , Amarillo, United States , Arlington, United States , Austin, United States , Beaumont, United States , Bedford, United States , Birmingham, United States , Burien, United States , Chicago, United States and 54 more locations